Short answer
SHOULDER INNOVATIONS, INC. (SI) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Jon Osborne appointed Chief Commercial Officer, signaling a commercial leadership change.
SHOULDER INNOVATIONS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Jon Osborne appointed Chief Commercial Officer, signaling a commercial leadership change
- Appointment may influence sales execution and go-to-market priorities
- Press release furnished as Exhibit 99.1 on August 10, 2026
Item EX-99.1 · Exhibit EX-99.1
- Jon Osborne promoted to Chief Commercial Officer, effective August 6, 2026
- Expanded mandate covering all commercial operations, Customer Experience, and Medical Education
- Leadership move supports scaling surgeon adoption and distribution of Shoulder Innovations’ shoulder implant portfolio
- Osborne brings orthopedic commercial experience from Smith & Nephew, ArthroCare, Tornier USA, and Team Surgical
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SHOULDER INNOVATIONS, INC. 8-K filings
Get the next SI 8-K as it lands
Follow SI for push alerts, or ask the research agent what this filing means.